Indeed, high serum levels of CXCL8 and IL-6 in melanoma have been associated with melanoma progression (22), higher tumor burden (54–57), and shorten PFS and OS in patients treated with biochemotherapy (54–56), Ipilimumab (57–59) and Nivolumab (58, 59). The gene discussed is CXCL8; the disease is melanoma.